X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VLS-01 (dimethyltryptamine) is a partial agonist of the 5-HT 1A/2A/2C receptors. It is currently being evaluated in the Phase I clinical trial studies for the treatment of resistant depression.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: VLS-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
The proceeds will advance short-duration psychedelic candidates, BPL-003 (mebufotenin), a novel, intranasal formulation of 5-methoxy-N,N-dimethyltryptamine, and ELE-101, a novel intravenous formulation of psilocin, by adding them to atai’s mental health innovation platform.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 04, 2024
Details:
EMP-01 (3,4-methylenedioxy-methamphetamine) is R-enantiomer of MDMA, which is under phase 1 clinical development for the treatment of Post-Traumatic Stress Disorder (PTSD).
Lead Product(s): R-3,4-methylenedioxymethamphetamine
Therapeutic Area: Psychiatry/Psychology Product Name: EMP-01
Highest Development Status: Phase IProduct Type:
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
VLS-01 is a proprietary OTF formulation of N,N-dimethyltryptamine. Pharmacologically, DMT is a partial agonist of the 5-HT 1A/2A/2C receptors, characterized by an intrinsically short duration of psychedelic effect, with a serum half-life estimated at less than 10 minutes.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: VLS-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
PCN-101 (R-ketamine), a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Perception Neuroscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA receptor antagonist.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
GRX-917 (etifoxine deuterated) increases the activation of selected subunits of GABAA channels, boosting GABAergic transmission via preferential positive allosteric modulation of β2/3-subunit-containing GABA receptors.
Lead Product(s): Etifoxine Deuterated
Therapeutic Area: Psychiatry/Psychology Product Name: GRX-917
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
PCN-101 (R-ketamine), demonstrated an encouraging safety profile and signals of efficacy across all timepoints despite not achieving statistical significance on the primary endpoint.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
KUR-101 is an atypical opioid receptor modulator with a unique pharmacology that may make it safer for chronic use. Its deuteration improves its pharmacokinetic and overall safety profile while reducing dosing requirements.
Lead Product(s): KUR-101
Therapeutic Area: Neurology Product Name: KUR-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
RL-007 is an orally available compound that modulates cholinergic, glutamatergic and GABA-B receptors, thereby putatively altering the excitatory/inhibitory balance in the brain to produce pro-cognitive effects.
Lead Product(s): RL-007
Therapeutic Area: Psychiatry/Psychology Product Name: RL-007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
